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Human Monocytes Via Nuclear Factor Kappa-B Activation
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Objectives Our study investigated: 1) the contribution of nuclear factor kappa-B (NF-B) signaling pathway to the enhanced
inflammatory response observed in unstable angina (UA) patients with elevated levels of C-reactive protein
(CRP); and 2) whether CRP may have direct proinflammatory effects via NF-B activation.
Background Unstable angina patients with elevated CRP have enhanced inflammatory response and increased risk of persis-
tent instability, myocardial infarction, and death.
Methods We studied 28 patients with history of UA and persistently elevated CRP (3 mg/l) followed for 24 months
and free of symptoms for at least 6 months (group 1), 14 patients with history of UA and low CRP (group
2), and 24 patients with chronic stable angina and low CRP (group 3). Peripheral blood monocytes were
analyzed for spontaneous NF-B activation and interleukin (IL)-6 and tumor necrosis factor (TNF)- produc-
tion. To assess the direct proinflammatory effects of CRP, monocytes from 8 healthy subjects were stimu-
lated in vitro with increasing doses of CRP (5 to 10 to 25 g/ml), lipopolysaccharide (LPS) (1 to 10 ng/ml),
or both.
Results Spontaneous NF-B activation in vivo was demonstrated in 82% of group 1 versus 14% of group 2 and 21% of
group 3 patients (p  0.001). Interleukin-6 and TNF- production was significantly correlated with the NF-B ac-
tivation status (r  0.55, p  0.001 and r  0.53, p  0.006, respectively). Patients with NF-B activation had
recurrence of acute coronary events (60% vs. 28%; p  0.017). C-reactive protein induced a significant but mod-
est in vitro NF-B activation in human monocytes (p  0.002). Coincubation with LPS produced a greater-than-
additive response (p  0.01 vs. CRP and LPS alone).
Conclusions Nuclear factor kappa-B activation might represent a mechanism by which CRP amplifies and perpetuates the
inflammatory component of acute coronary syndromes and influences the clinical outcome. (J Am Coll Cardiol
2007;49:185–94) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.071u
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rrowing evidence suggests that C-reactive protein (CRP)
redicts short- and long-term outcome in patients with
cute coronary syndromes (ACS), independently of other
iohumoral risk markers (1–6). Furthermore, patients with
rom the *Institute of Cardiology, Catholic University, Rome, Italy; and the †Diparti-
ento Cardiotoracovascolare, Universitá “Vita e Salute,” Milan, Italy. This study was
upported by Fondazione Internazionale di Ricerca Per il Cuore onlus, Rome, Italy.t
Manuscript received March 29, 2006; revised manuscript received July 10, 2006,
ccepted July 17, 2006.nstable angina (UA) and persistently high levels of CRP
xhibit enhanced inflammatory cell reactivity both in vivo in
esponse to coronary angiography, percutaneous coronary
ntervention (7) and myocardial necrosis (8) and in vitro in
esponse to lipopolysaccharide (LPS) challenge (9).
See page 195
Nuclear factor kappa-B (NF-B) is a pivotal transcrip-
ion factor that may play a key role in plaque instability by
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CRP, NF-B, and Unstable Angina January 16, 2007:185–94promoting the expression of a
cascade of procoagulant and
proinflammatory genes in re-
sponse to a variety of stimuli
(10–13). Accordingly, Ritchie
(14) has demonstrated that
NF-B is activated in circulating
leukocytes of patients with ACS
but not in leukocytes of stable
angina patients, and Cominacini
et al. (15) have recently found
that the activation of NF-B in
monocytes of UA is, at least in
part, induced by circulating mol-
cules such as oxidized low-density lipoproteins (ox-LDL).
ctivated NF-B has been identified in monocyte/
acrophages, smooth muscle cells, and endothelial cells in
uman atherosclerotic vessels, but not in healthy vessels
11), and is enhanced in coronary plaques of patients with
A (16). Coronary plaques from patients with ACS exhibit
ncreased expression of several NF-B–regulated genes,
ncluding proinflammatory cytokines, growth factors, che-
okines, adhesion molecules, and tissue factor (12).
-reactive protein is also present in atherosclerotic plaques
17–19) and exhibits a range of proinflammatory properties
hat could directly contribute to pathogenesis, progression,
nd complications of the atheroma (20–22).
Therefore, the aim of the present study was 2-fold: 1) to
xplore the contribution of NF-B signaling pathway to the
nhanced inflammatory response observed in patients with
A and elevated levels of CRP (protocol A); and 2) to
ssess whether CRP may have direct proinflammatory
ffects on human circulating leukocytes via NF-B activa-
ion (protocol B).
ethods
opulation. PROTOCOL A. Three groups of subjects were
rospectively studied. Group 1 included 28 consecutive
atients (mean age 64  10 years, 17 men) with a history of
A and persistently elevated levels of CRP (3 mg/l) over
he following 24 months, measured in plasma samples
btained at the time of hospital admission, at discharge, and
very 3 months after discharge. Group 2 included 14
onsecutive patients (mean age 66  9 years, 10 men) with
history of UA and persistently normal levels of CRP over
he following 24 months, measured at the same time points
s in group 1. Group 3 included 24 consecutive patients
mean age 59  9 years, 19 men) with stable angina and
ormal CRP (3 mg/l).
All patients fulfilled the following inclusion criteria: 1) no
cute coronary events in the 6 months before study entry; 2) no
vidence of inflammatory or infectious diseases, malignancies,
r immunologic or hematologic disorders; 3) no treatment
ith anti-inflammatory drugs other than low-dose aspirin; 4)
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CRP  C-reactive protein
IL  interleukin
LPS  lipopolysaccharide
NF-B  nuclear factor
kappa-B
TNF  tumor necrosis
factor
UA  unstable anginajection fraction 40%; and 5) age 75 years. NPatients were followed for a further period of 12 months
fter enrollment to assess the clinical outcome. Follow-up
isits, consisting of physical examination, a standard 12-lead
lectrocardiogram, and a treadmill stress test, were per-
ormed every 3 months. Recurrence of new acute coronary
vents (cardiac death, myocardial infarction, and coronary
are unit admission for UA) was recorded.
ROTOCOL B. To assess whether CRP may have direct
roinflammatory effects on human circulating mononuclear
ells via NF-B activation, a smaller study was designed
ncluding 8 healthy volunteers (mean age 49  5 years,
men) without coronary risk factors. In particular, subjects
ith acute or chronic inflammatory or infectious diseases,
alignancies, immunologic or hematologic disorders, treat-
ent with anti-inflammatory drugs, or recent (6 months)
urgery or trauma were excluded.
All subjects gave their written informed consent. The
thics committee of the Catholic University of Rome
pproved the study.
lood sampling and monocyte isolation. PROTOCOL A. In
ll patients, a venous blood sample was obtained at the time of
tudy entry for the following analyses: 1) CRP plasma levels
nd IL-6 and TNF- serum levels; 2) total and differential
hite blood cell counts; and 3) monocyte isolation. In 16
atients of group 1, 10 patients of group 2, and 14 patients of
roup 3, a further blood sample for total and differential white
lood cell counts and monocyte isolation was obtained at 12
onths follow-up.
Isolation of peripheral blood monocytes was performed by
radient centrifugation layering 30 ml heparinized (10 U/ml)
lood over NycoPrep (Life Technologies, Rockville, Mary-
and) (9). Isolation of 80% pure monocytes was obtained, as
valuated by using flow cytometry (data not shown).
Freshly isolated peripheral blood monocytes (5 105) were
nalyzed for spontaneous NF-B activation (see succeeding
ext) and for IL-6 and TNF- production after in vitro
timulation, as previously described (9). Briefly, monocytes
ere incubated for 4 h at 37°C in RPMI-1640 supplemented
ith 10% fetal calf serum, 50 U/ml penicillin, 50 g/ml
treptomycin, and 0.2 mmol/l L-glutamine. Cells were stim-
lated with low dose of LPS (1 ng/ml, Escherichia coli 011:B4;
igma Chemical Co., St. Louis, Missouri), which reflects the
PS concentration detected during clinical infections (23).
fter 4 h incubation, the culture supernatant was removed and
tored at 80°C for further analysis.
ROTOCOL B. In the 8 healthy volunteers, 40 ml heparinized
enous blood was obtained at the time of study entry for
onocyte isolation, which was performed as described in
rotocol A. In vitro studies were carried out using recombinant
uman C-reactive protein (rhCRP) and/or highly purified
RP isolated from human serum, as specifically indicated.
ecombinant human CRP (from Escherichia coli, 99% of
urity) was obtained from Calbiochem (La Jolla, California)
nd was supplied in 20 mmol/l Tris-HCl, pH 7.5, 140 mmol/l
aCl, 2 mmol/l CaCl2, and 0.05% NaN3. Recombinant
h
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January 16, 2007:185–94 CRP, NF-B, and Unstable Anginauman CRP was used in electrophoresis mobility shift assay
EMSA). Highly purified (99%) native pentameric CRP
solated from human serum was also obtained from Calbio-
hem and was supplied in 10 mmol/l Tris, pH 8.0, 140 mmol/l
aCl, 2 mmol/l CaCl2, and 0.1% NaN3. Purified CRP was
sed for enzyme-linked immunosorbent assay (ELISA) and
onfocal microscopy.
Aliquots of 5  105 cells were incubated at 37°C in
hosphate-buffered solution (PBS) and stimulated with in-
reasing doses of CRP alone (5 to 10 to 25 g/ml), either
hCRP (EMSA) or purified CRP (ELISA, confocal micros-
opy) (see succeeding text), LPS alone (10 ng/ml), or both for
0 min to assess the effects on NF-B activation. A cell aliquot
as preincubated with 50 mmol/l pyrrolidine dithiocarbamate
PDTC) (Calbiochem, La Jolla, California), a NF-B inhib-
tor, for 1 h before CRP stimulation (25 g/ml) for 30 min.
ells were also stimulated with CRP (25 g/ml) denatured by
ncubation in boiling water bath for 1 h.
pecificity of the CRP preparations used for in vitro
tudies. The following strategies were used to determine
he specificity of both the CRP preparations used for in
itro studies: 1) the purity of CRP preparations was further
onfirmed by sodium dodecyl sulfate-polyacrylamide gel
lectrophoresis (SDS-PAGE) (a single band on silver-
tained and overloaded gels); 2) to remove the azide from
RP preparations, 1 mg was dialyzed twice against 500 ml
f the Tris/NaCL/CaCL2 buffer; 3) endotoxin was removed
rom CRP with a detoxigel column (Pierce Biochemicals,
ockford, Illinois), and all the reagents used were endotoxin
ree according to the limulus test (sensitivity 0.06 U/ml;
igma); 4) the cell cultures stimulated with CRP were
oincubated with Polymixin B (10 g/ml) to insure that
RP-induced effects were distinct from those mediated by
PS; and 5) CRP was denatured by incubation in boiling
ater bath for 1 h (denatured CRP). The CRP doses used
n this study corresponded to CRP plasma concentrations
etected in UA patients (1–5).
easurements. ASSESSMENT OF NF-B ACTIVATION. Elec-
rophoresis mobility shift assay (EMSA). In unstimulated cells,
F-B dimers are found in the cytoplasm in an inactive form
ound to inhibitory proteins that prevent NF-B dimers from
ntering the nuclei. Proinflammatory stimuli initiate a rapid
ellular signaling pathway in which specific kinases phosphor-
late the NF-B inhibitory proteins, causing their rapid deg-
adation. The release of NF-B from the inhibitory proteins
esults in the passage of NF-B dimers into the nucleus, where
hey bind to specific sequences in the promoter region of target
enes, thus starting the process leading to protein synthesis.
he activated form of NF-B is a heterodimer that usually
onsists of a p65 and a p50 subunit (10).
Nuclear presence of NF-B complexes can be demonstrated
n mobility shift assays (24). Nuclear extracts from 5  105
onocytes were prepared by use of a high-salt extraction
rotocol, and electrophoretic mobility shift assays were per-
ormed as described (25). Nuclear extract (5 g) was combined
ith 15l binding buffer, 1.5g poly(dI-dC) (Sigma), and 1.5 mg nonspecific oligonucleotide (5=-TCGAAGTAC-
CAATTGCTCGAGATCGAT-AGATCTGAA-
TCAGTACTCC-3=). In supershift assays, 1 g of a p50
ubunit-specific antibody (Upstate Biotechnology, Charlottes-
ille, Virginia) or irrelevant mouse IgG1 (Sigma) was added to
he reaction. Total volume of reaction mixture was adjusted to
5 l, and the mixture was left on ice for 30 min. Specific
ouble-stranded oligonucleotide probe corresponding to
F-B binding site (5=-AGTTGAGGGGACTTT-
CCAGGC-3=) (24) was radiolabeled with [-32P] adeno-
ine triphosphate (NEN, Boston, Massachusetts) by standard
nd-labeling reaction. Annealed probes at a final concentration
f 40 fmol/l were added to the reaction and incubated at
oom temperature for 30 min. Protein-DNA complexes were
esolved on 6% nondenaturing polyacrylamide gels, visualized
sing a PhosphorImager screen (Molecula Dynamics, San
ose, California), and quantified using Imagequant software
National Institutes of Health, Bethesda, Maryland). As a
ositive control, we used nuclear extracts from 5  105
onocytes incubated for 30 min with 10 ng/ml LPS and as a
egative control nuclear extracts from 5  105 monocytes
ncubated for 30 min with PBS only.
LISA FOR ACTIVE NF-B P65. The amount of activated
F-B p65 subunit in nuclear extract (5 g), prepared from 5
105 monocytes (as described in preceding text) was assessed
y a sensitive ELISA assay for active NF-B (TRANS-AM,
ctive Motif, Rixensart, Belgium). The NF-B ELISA kits
ontain a 96-well plate on which has been immobilized
ligonucleotide containing the NF-B consensus site (5=-
GGACTTTCC-3=). The active form of NF-B contained
n nuclear-cell extract specifically binds to this oligonucleotide.
he primary antibodies used to detect NF-B recognize an
pitope on p65 that is accessible only when NF-B is activated
nd bound to its target DNA. A horseradish peroxidase-
onjugated secondary antibody provides a sensitive col-
rimetric readout that is easily quantified by spectropho-
ometry by reading within 5 min the absorbance at 450
m with a reference wavelength of 650 nm. The assay is
pecific for NF-B activation and has been shown to be
0-fold more sensitive and 40-fold faster than the gel
etardation technique: detection limit 0.5 g nuclear-
ell extract/well; range of detection 0.2 to 5 g of
uclear-cell extract/well. The Jurkat nuclear extract is
sed as a positive control for NF-B activation. The
ild-type consensus oligonucleotide is used as a competitor for
F-B binding to monitor the specificity of the assay; at 20
mol/well it will prevent NF-B binding to the probe immobi-
ized on the plate, and, conversely, the mutated consensus oligo-
ucleotide has no effect on NF-B binding.
ONFOCAL MICROSCOPY. The activation of NF-B was also
etermined by confocal microscopy assessing the nuclear lo-
alization of the p65 NF-B subunit. After stimulation with
RP alone (25 g/ml), LPS alone (10 ng/ml), or both for 30
in, as described in the preceding text, aliquots of 5  104onocytes were resuspended in 200 l RPMI 1640 with 1%
f
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CRP, NF-B, and Unstable Angina January 16, 2007:185–94etal calf serum and permitted to adhere to chamber slides
Nalgene Nunc) for 30 min at room temperature. Then cells
ere fixed in PBS  4% formaldehyde for 10 min at
oom temperature, permeabilized with 0.1% Triton
-100, and stained. Cells were incubated for 1 h at room
emperature with a 1:100 dilution of mouse monoclonal
ntihuman primary antibody for p65 (sc-8008; Santa
ruz Biotechnology, Santa Cruz, California) in blocking
uffer, then they were rinsed and incubated in the dark
or 1 h with a 1:100 dilution of FITC-conjugated goat
ntimouse IgG secondary antibodies. Nuclei were stained
ith the fluorescent dye 4-,6-diamidino-2-phenylindole
ihydrochloride (DAPI). The stained cells were analyzed
ith the Olympus FV500 confocal laser-scanning micro-
cope (Olympus Deutschland, Hamburg, Germany); 3
mages were obtained from different regions of each
tained slide. Cells were scored as either positive or
egative for nuclear p65, and the percentage of cells
ositive for nuclear p65 was determined. The percentage
f cells with p65 subunit accumulated in the nucleus was
alculated from at least 100 DAPI nuclei counted for
ach region.
EASUREMENTS OF CRP AND CYTOKINES. CRP was mea-
ured with a high-sensitivity latex-enhanced immunonephelo-
etric assays (Dade Behring, Marburg, Germany) (3). The
edian normal value for CRP is 0.8 mg/l, with 90% of all
alues in healthy subjects 3 mg/l. Interleukin-6 and TNF-
ere measured with a commercial assay kit (Quantikine
uman IL-6 and Quantikine human TNF-; R&D Systems,
inneapolis, Minnesota) (26). Interleukin-6 and TNF-
easurements were performed in duplicate, and the intra- and
nterassay variability was 10%. The range of values detected
y the assay was 3 to 300 pg/ml for IL-6 and 15.6 to 1,000
g/ml for TNF-. Total and differential white blood cell
ounts were obtained with a hematology analyzer by using
utomated cytochemistry in flow.
tatistical analysis. Because CRP, IL-6, and TNF- values
o not follow a normal distribution, nonparametric tests were
sed (the Mann-Whitney U test for comparisons between
roups and the Spearman rank correlation test to determine
orrelations). The remaining continuous variables were com-
ared by using analysis of variance (ANOVA) for comparisons
etween different groups and ANOVA for repeated measures
ithin groups, with the Tukey test correction as appropriate
nd as suggested by the statistical software used. Proportions
ere compared with the Fisher exact test. The CRP, IL-6, and
NF- values are expressed as medians and ranges; the
emaining variables are expressed as mean SD. A p value of
0.05 (2-tailed) was considered to be statistically significant.
ll statistical analysis was performed with SigmaStat software
SPSS Inc., Chicago, Illinois).
esults
rotocol A. Patient demographic and clinical data are
ummarized in Table 1. (Spontaneous NF-B activation as assessed by EMSA was
bserved in 23 of 28 (82%) group 1 patients, in 2 of 14 (14%)
roup 2 patients, and in 5 of 24 (21%) group 3 patients (p 
.001; group 1 vs. group 2 and group 3) (Fig. 1A). Quantifi-
ation of activated NF-B p65 subunit by ELISA showed a
tatistically significant difference between group 1 and the
ther groups (p  0.009; ANOVA with Tukey test adjust-
ent for comparisons between the 3 groups) (Fig. 1B).
oreover, after 12 months of follow-up NF-B activation was
etected in 81% of group 1 patients, 20% of group 2 patients,
nd 21% of group 3 patients who had a second determination
f NF-B activation status (p 0.002; group 1 vs. group 2 and
roup 3). The concordance between the 2 determinations was
lmost complete (with only 1 patient of group 3 initially
egative becoming positive).
In the overall population, IL-6 and TNF- production in
esponse to LPS (1 ng/ml) was significantly correlated with
aseline levels of CRP (r  0.49; p  0.005; and r  0.58; p
0.003; respectively) and with the NF-B activation status (r
0.55; p  0.001; and r  0.53; p  0.006; respectively).
ccordingly, serum levels of CRP and production of IL-6 and
NF- in response to LPS were significantly higher in
atients with than in those without NF-B activation (Fig. 2).
he CRP levels were 10.4 (0.9 to 67.5) mg/l in patients with
nd 1.3 (0.2 to 10.8) mg/l in patients without NF-B activa-
ion (p  0.001). The IL-6 production was 7.5 (2.0 to 25.7)
g/ml in patients with and 2.4 (0.2 to 13.0) ng/ml in patients
ithout NF-B activation (p  0.001). The TNF- produc-
ion was 1.4 (1.1 to 3.2) ng/ml in patients with and 1.1 (0.09
o 1.6) ng/ml in patients without NF-B activation (p 
.006). No differences were observed in total and differential
hite blood cell counts between patients with and patients
ithout NF-B activation (data not shown).
Finally, 18 of 30 patients (60%) with persistent activation
f NF-B versus 10 of 36 patients (28%) without NF-B
ctivation (p  0.017) had recurrence of acute coronary
vents (14 patients with and 8 patients without NF-B
ctivation had recurrence of UA; 3 patients with and 2
atients without NF-B activation had myocardial infarc-
ion; 1 patient with NF-B activation died) during the
ollow-up period. None of the other analyzed clinical
ariables (demographic data, risk factors, medications [in-
luding statins], severity of coronary disease, previous PCI
r CABG) was associated with the presence of NF-B
ctivation (data not shown).
rotocol B. Incubation of the radioactive NF-B binding
ite-specific probe with nuclear proteins isolated from hu-
an monocytes resulted, when analyzed by EMSA, in a
ingle shifted band that was barely detectable in unstimu-
ated cells, was markedly induced by stimulation with LPS
10 ng/ml) as expected, but was also induced by stimulation
ith increasing doses of rhCRP (5 to 10 to 25 g/ml), and
nhibited by preincubation with PDTC (50 mmol/l) and by
he use of denatured rhCRP (Fig. 3A). Coincubation of
oth rhCRP and LPS had a greater-than-additive effect
Fig. 3B). Gel supershift experiments with monoclonal
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January 16, 2007:185–94 CRP, NF-B, and Unstable Anginantibodies to p50 subunit indicated that complexes con-
isted of heterodimers containing the p50 subunit (Fig. 3).
uantification of the nuclear expression of the activated
F-B p65 subunit was performed by ELISA and
xpressed as optical density (OD) at 450 nm. Purified
RP, used for the ELISA at the increasing doses of 5 to
0 to 25 g/ml, induced a slight but significant increase
n NF-B p65 expression (p  0.002; ANOVA for
epeated measures with the Tukey test adjustment for the
5 comparisons included) up to a mean  SD value of 0.174
0.164 OD with the dose of 25 g/ml, 75% over the basal
alue (0.099  0.081 OD) (Fig. 4A). Pretreatment with the
F-B inhibitor PDTC prevented the NF-B activation
nduced by purified CRP (0.100  0.091 OD, percentage
nhibition 42%; p  0.78 vs. basal value), as well as the use of
enatured CRP (0.092  0.072 OD; percentage inhibition
7%; p  0.61 vs. basal value) (Fig. 4A). Lipopolysaccharide
lone, at the low dose of 10 ng/ml, induced a mean increase in
F-B p65 expression of 0.133  0.126 OD (35% over the
asal value; p  0.042). Coincubation of purified CRP with
PS induced a further increase in NF-B expression, partic-
larly evident with 25g/ml of CRP (p 0.001; ANOVA for
epeated measures with the Tukey test adjustment for the 10
Demographic and Clinical Characteristics of Uns
Table 1 Demographic and Clinical Characte
Patients, n
Age, yrs, mean  SD
Gender, male/female
Risk factors, n (%)
Family history of ischemic heart disease
Hypercholesterolemia
Diabetes
Hypertension
Smoking
Medications, n (%)
Oral nitrates
Beta-blockers
Calcium blockers
ACE inhibitors
Aspirin
Other antiplatelet agents
Lipid-lowering agents
Multi-vessel disease, n (%)
Previous percutaneous coronary interventions, n (%)
Previous coronary artery bypass graft, n (%)
Recurrence of acute coronary events, n (%)
CRP levels at the time of study entry, mg/l
IL-6 levels at the time of study entry, pg/ml
TNF- levels at the time of study entry, pg/ml
Spontaneous NF-B activation, n (%)
Group 1  28 patients with a history of unstable angina and persisten
unstable angina and normal levels of CRP; group 3  24 patients with
are presented as median (range). *p 0.001, group 1 versus group 3;
group 2 and group 3.
ACE angiotensin-converting enzyme; CRP C-reactive protein; IL inteomparisons included), up to a mean value of 0.257  0.162 aD (159% over the basal value), which was significantly
reater than that observed with LPS alone (p 0.001) or CRP
lone (p  0.003) (Fig. 4B).
Moreover, in 3 healthy volunteers we analyzed the nu-
lear accumulation of p65 in the presence of purified CRP
25 g/ml), LPS (10 ng/ml), or both, by using confocal
icroscopy of monocytes stained with FITC-labeled anti-
ody against p65. To identify the nucleus, monocytes were
tained with DAPI. In nonstimulated monocytes, p65 was
istributed throughout the cytosol. After stimulation with
urified CRP and LPS, p65 consistently disappeared
rom the cytosol and accumulated in the nucleus, espe-
ially after costimulation with both of them. After
reatment of monocytes with denatured CRP, the pattern
f the p65 subcellular distribution was similar to that in
he nonstimulated cells (Fig. 5A). Then, cells were scored
s either positive or negative for nuclear p65. The
ercentage of cells positive for nuclear p65 was 12% at
aseline (untreated cells), 22% after CRP stimulation,
0% after LPS stimulation, and close to 50% after
reatment with both CRP and LPS, and it was reduced to
6% when denatured CRP was used (p  0.001;
NOVA for repeated measures with the Tukey test
and Stable Angina Patients
s of Unstable and Stable Angina Patients
Group 1 Group 2 Group 3
28 14 24
64 10 66 9 59 9
17/11 10/4 19/5
(57) 6 (43) 10 (42)
(39) 6 (43) 13 (54)
(32) 3 (21) 8 (33)
(54) 9 (64) 11 (46)
(64) 8 (57) 13 (54)
(25) 5 (36) 6 (25)
(75) 11 (79) 20 (83)
(21) 4 (29) 4 (17)
(71) 9 (64) 16 (67)
(86) 13 (93) 21 (88)
(46) 7 (50) 10 (42)
(68) 10 (71) 15 (63)
(43) 8 (57) 13 (54)
(64) 8 (57) 8 (33)
(29) 4 (29) 12 (50)
(68)* 6 (43) 3 (13)
(3.1–67.5)† 1.3 (0.8–2.1) 1.2 (0.2–2.9)
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ated levels of CRP (3 mg/l); group 2  14 patients with a history of
c stable angina and normal levels of CRP. CRP, IL-6, and TNF- levels
.001, group 1 versus group 2 and group 3; ‡p 0.05, group 1 versus
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ur study demonstrates that, 6 months or longer after
he last acute coronary event, in an apparently stable
hase of the disease, circulating monocytes from UA
atients with persistently elevated levels of CRP express
Figure 1 Assessment of Spontaneous NF-B Activation in Circu
(A) Electrophoresis mobility shift assay (EMSA). In each patient, freshly isolated p
activated nuclear factor (NF)-B complexes in their nuclei by EMSA in the presence
As a positive control (Pos) nuclear extracts were generated from 5  105 monocy
control (Neg) nuclear extracts were generated from 5  105 monocytes incubated
p50 subunit were detected in 82% of group 1 patients, 14% of group 2 patients, a
shows the assessment of NF-B activation in 3 patients (Pt) of group 1 and in 3 p
p65. The amount of activated NF-B p65 subunit in nuclear extract (5 g), prepare
The activated NF-B p65 subunit was significantly higher in group 1 than in the oth
Figure 2 Inflammatory Response According to the NF-B Activ
Serum levels of CRP (A), and production of IL-6 (B) and TNF- (C) in response to
without (NF-B) NF-B activation. (B and C) Monocytes (5  105) were stimulate
was removed and stored at 80°C for IL-6 and TNF- measurements by ELISA. CR
tions as in Figure 1.n vivo activation and nuclear translocation of the tran-
cription factor NF-B. Moreover, CRP concentrations
nown to predict adverse clinical outcome in UA induce
F-B activation in vitro, as consistently shown using 3
ifferent methods. Although CRP-induced NF-B acti-
ation is modest, our findings consistently show that
g Monocytes (Protocol A)
ral blood monocytes (5  105) were analyzed for the spontaneous presence of
ti-p50 subunit monoclonal antibodies or isotype-matched control IgG antibodies.
ubated for 30 min with 10 ng/ml lipopolysaccharide (LPS), and as a negative
min with phosphate-buffered solution only. NF-B heterodimers containing the
% of group 3 patients (p  0.001; group 1 vs. group 2 and group 3). The figure
of group 2. (B) Enzyme-linked immunosorbent assay (ELISA) for active NF-B
5  105 monocytes was assessed by a sensitive ELISA assay for active NF-B.
ups. ANOVA  analysis of variance; OD  optical density.
Status (Protocol A)
LPS challenge were significantly higher in patients with (NF-B) than in those
a low dose of LPS (1 ng/ml); after 4 h of incubation, the culture supernatant
-reactive protein; IL  interleukin; TNF  tumor necrosis factor; other abbrevia-latin
eriphe
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January 16, 2007:185–94 CRP, NF-B, and Unstable AnginaRP is able to amplify the effect of a standard proin-
ammatory stimulus, such as a low dose of LPS, produc-
ng a greater-than-additive response. Thus, NF-B acti-
ation might represent a mechanism by which CRP
Figure 3 CRP Induction of NF-B Activation in Circulating Mon
In 8 healthy volunteers, aliquots of 5  105 cells were incubated at 37°C in PBS
g/ml) for 30 min to assess the effects on NF-B activation. A cell aliquot was inc
before CRP stimulation (25 g/ml), and another cell aliquot was stimulated with C
itive control (Pos) nuclear extracts were generated from 5  105 monocytes incub
were generated from 5  105 monocytes incubated for 30 min with PBS only. As
induced by stimulation with increasing doses of rhCRP and inhibited by preincubat
both rhCRP and LPS had a greater-than-additive effect (B). Gel supershift experime
sisted of heterodimers containing the p50 subunit. Other abbreviations as in Figur
Figure 4 CRP Amplified the Effect of LPS on NF-B Activation
Quantification of the nuclear expression of the activated NF-B p65 subunit was p
as described in Figure 3. Purified CRP, used for the ELISA at the increasing doses
sion (p  0.002) up to a mean  SD value of 0.174  0.164 OD with the dose o
NF-B inhibitor PDTC prevented the NF-B activation induced by purified CRP, as w
sus the basal value; **p  0.01, purified CRP 25 g/ml versus PDTC inhibition a
 SD increase in NF-B p65 expression of 0.133  0.126 OD (35% over the basa
increase in NF-B expression, particularly evident with 25 g/ml of CRP, up to a m
cantly greater than that observed with LPS alone (‡p  0.001) or CRP alone (§p mplifies and perpetuates the inflammatory component of
CS, and influences the clinical outcome, because pa-
ients with NF-B activation had recurrence of acute
oronary events over 1 year of follow-up.
s as Assessed by EMSA (Protocol B)
imulated with increasing doses of recombinant human (rh) CRP (5 to 10 to 25
d with the NF-B inhibitor pyrrolidine dithiocarbamate (PDTC) (50 mmol/l) for 1 h
5 g/ml) denatured by incubation in boiling water bath for 1 h (25den). As a pos-
r 30 min with 10 ng/ml LPS, and as a negative control (Neg) nuclear extracts
in this representative EMSA, NF-B activation in circulating monocytes was
h PDTC (50 mmol/l) and by the use of denatured rhCRP (A); coincubation of
ith monoclonal antibodies to the p50 subunit indicated that complexes con-
nd 2.
ocol B)
ed by ELISA and expressed as OD at 450 nm. The experimental conditions are
o 10 to 25 g/ml, induced a slight but significant increase in NF-B p65 expres-
g/ml, 75% over the basal value (0.099  0.081 OD). Pretreatment with the
the use of denatured CRP (25den) (A); *p  0.05, purified CRP 25 g/ml ver-
atured CRP (25den). LPS alone, at the low dose of 10 ng/ml, induced a mean
e; †p  0.042). Coincubation of purified CRP with LPS induced a further
SD value of 0.257  0.162 OD (159% over the basal value), which was signifi-
3) (B). Abbreviations as in Figures 1 and 2.ocyte
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estabilization. NF-B is a pivotal transcription factor in-
olved in the induction of specific proinflammatory genes (10).
t was recently suggested that NF-B may be critical in plaque
nstability by transducing pathogenic stimulation to expression
f genes that promote recruitment and activation of inflam-
atory cells in the coronary plaques (12). Activation of NF-B
ay occur after stimulation of lesional cells by pathogenically
elevant factors such as proinflammatory cytokines, TNF-
nd IL-1, bacterial LPS, viruses, components of microorgan-
sms such as Chlamydia pneumoniae, and reactive oxygen
pecies involved in low-density lipoprotein oxidation (11–13).
ctivated NF-B has been identified in monocyte/
acrophages, smooth muscle cells, and endothelial cells in
uman atherosclerotic vessels, but not in healthy vessels (11),
nd is enhanced in ACS (16). Plaques from patients with ACS
xhibit increased expression of several NF-B–regulated genes,
ncluding the cytokines TNF- and IL-1 (which induce
Figure 5 Confocal Microscopy Assessment of NF-B Activation
In 3 healthy volunteers, the nuclear accumulation of p65 in the presence of purifie
monocytes (MO) stained with FITC-labeled antibody against p65. To identify the nu
(DAPI). (A) In nonstimulated monocytes, p65 was distributed throughout the cytos
cytosol and accumulated in the nucleus, especially after costimulation with both. A
distribution was similar to that in the nonstimulated cells. (B) Cells were scored a
nuclear p65 was calculated from at least 100 DAPI nuclei (counted for each of the
nuclear p65 was 12% at baseline (unstimulated cells), 22% after stimulation with
ment with both CRP and LPS, and it was reduced to 16% when denatured CRP wa
**p  0.01, treatment with both CRP and LPS versus baseline, CRP alone, and LF-B activation in a positive feedback loop), IL-6 (the major anducer of acute-phase protein production), interferon- (the
ost powerful activator of mononuclear cells), growth factors
stimulating smooth muscle cell proliferation), chemokines,
dhesion molecules, and tissue factor (a major initiator of the
oagulation cascade) (12).
Our data confirm and expand the previous observation by
itchie (14), who demonstrated NF-B activation in circu-
ating monocytes of patients with UA in the acute phase of
nstability. Indeed, we found NF-B activation in a subset
f patients with persistent elevation of CRP plasma levels
ong after an episode of coronary instability. We also found
n association between persistent NF-B activation and
ecurrence of acute coronary events.
RP and NF-B. Our study is the first to establish a link
etween CRP levels—NF-B activation—and proinflam-
atory status in UA. It is also the first study to indicate that
RP, at concentrations commonly observed in UA, signif-
cantly induces NF-B activation in circulating monocytes,
tocol B)
(25 g/ml), LPS (10 ng/ml), or both was assessed by confocal microscopy of
monocytes were stained with 4-,6-diamidino-2-phenylindole dihydrochloride
r stimulation with purified CRP and LPS, p65 consistently disappeared from the
eatment of monocytes with denatured CRP, the pattern of the p65 subcellular
r positive or negative for nuclear p65, and the percentage of cells positive for
ions analyzed from each stained slide). The percentage of cells positive for
d CRP alone, 30% after stimulation with LPS alone, and close to 50% after treat-
(25den) (p  0.001). *p  0.01, stimulation with LPS alone versus baseline;
ne. Other abbreviations as in Figures 1 and 2.(Pro
d CRP
cleus,
ol. Afte
fter tr
s eithe
3 reg
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PS alomplifying the effects of a standard proinflammatory stim-
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January 16, 2007:185–94 CRP, NF-B, and Unstable Anginalus, such as a low dose of LPS. Despite the many reports
egarding the cellular and biologic phenomena induced by
RP, their intracellular signal transduction pathways re-
ain to be determined. In previous studies, CRP was found
o induce NF-B activation in rat vascular smooth muscle
ells (27), bovine aortic endothelial cells (28), and human
aphenous vein endothelial cells (29), but at doses markedly
igher than the plasma concentration range observed in
atients with ACS. C-reactive protein at doses 10 g/ml
lso induces the expression of the chemokine IL-8, a
owerful trigger of monocyte adhesion to endothelium, in
uman aortic endothelial cells and human coronary artery
ndothelial cells via up-regulation of NF-B activity (30).
hus, the present data on circulating monocytes together
ith the available data on endothelial cells suggest that at
east some of the detrimental effects of CRP promoting
laque instability might be mediated via the activation of
he NF-B signaling pathway.
Indeed, several effects of CRP, which has been found
ithin atherosclerotic plaques (17–19), might directly con-
ribute to plaque instability. First, the capacity of aggregated
nd ligand-complexed human CRP to activate the classic
omplement pathway and thus to express the major opsonic
nd chemotactic functions of the complement system has
ong been known (20,31). Second, bound CRP may be
ecognized by a subset of cellular Fc() receptors (18) and
hus directly activate phagocytic cells, as previously demon-
trated for high concentrations of CRP (32,33) and con-
rmed in a previous study by our group for concentrations
nown to predict increased vascular event rates (9). Third,
RP has been reported to stimulate tissue factor production
y peripheral blood monocytes and could thereby have
mportant procoagulant effects (34,35). Fourth, CRP di-
ectly induces the expression of leukocyte adhesion mole-
ules and of monocyte chemoattractant protein 1 by human
ndothelial cells, an inflammatory effect that can be inhib-
ted by statins and PPAR- activators (36,37). Finally, CRP
as been shown to elicit several other detrimental effects on
ndothelial cells and/or vascular smooth muscle cells: it
timulates endothelin-1 and IL-6 production (38); it de-
reases PGI2 and nitric oxide release (39,40); it up-regulates
ngiotensin type 1 receptor expression, thus promoting cell
igration and proliferation in vitro and increasing reactive
xygen species production (41); and it inhibits endothelial
rogenitor cells differentiation, survival, and function, thus
ffecting key components of angiogenesis and response to
hronic ischemia (42). Interestingly, CRP in atherosclerotic
laques is bound to low-density lipoproteins (18,31), and
irculating ox-LDL have recently been shown to activate
F-B in monocytes of UA patients (15).
tudy limitations. Although potentially relevant for plaque
estabilization, many of the claimed in vitro effects of CRP
emain controversial because they might be caused by
ontaminants and/or additives in the CRP solution. Our
ndings may have similar limitations. However, differently
rom several previous studies, we used a number of strategieso ensure the specificity of CRP-mediated effects: the purity
f CRP preparations was further confirmed by SDS/PAGE;
RP preparations were dialyzed twice to remove sodium
zide; endotoxin was removed from CRP with a detoxigel
olumn and all the reagents used were endotoxin free
ccording to the limulus test; the cell cultures stimulated
ith CRP were coincubated with Polymixin B to ensure
hat CRP-induced effects were distinct from those mediated
y LPS; all the effects on NF-B disappeared when CRP
enatured by incubation in boiling water bath for 1 hour
as used; and 3 different methods were used to demonstrate
RP-induced NF-B activation. Finally, although rhCRP
as used for EMSA, the results obtained were confirmed by
LISA and confocal microscopy, where highly purified
RP isolated from human serum was used.
linical implications. We previously demonstrated that
atients with a history of UA and persistently high levels of
RP represent a subset of patients with enhanced proin-
ammatory responsiveness of circulating leukocytes to a
ariety of potential stimuli (7–9); those patients are also at
ery high risk of recurrence of acute coronary events (3).
he present study supports the notion that NF-B activa-
ion might represent a mechanism by which raised levels of
RP amplify and perpetuate the inflammatory component
f ACS and influence the clinical outcome. Indeed, our
atients with persistent NF-B activation had higher recur-
ence of acute coronary events during 12 months of
ollow-up than patients without NF-B activation.
Overall, the present findings may have clinical implica-
ions, because PPAR- agonists or other inhibitors of
F-B activation might result in new therapeutic ap-
roaches in ACS (43,44). The present data may also
xplain, at least partially, the beneficial effects of high-dose
tatins, because it has been consistently shown that high-
ose statins improve the outcome of patients with ACS in
ssociation with a marked reduction of CRP levels (45,46).
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nstitute of Cardiology, Catholic University, Largo A. Gemelli 8,
0168 Rome, Italy. E-mail address: gliuzzo@hotmail.com.
EFERENCES
1. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of
C-reactive protein and serum amyloid A protein in severe unstable
angina. New Engl J Med 1994;331:417–24.
2. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a
potent predictor of mortality independently of and in combination
with troponin T in acute coronary syndromes: a TIMI 11A substudy.
Thrombolysis In Myocardial Infarction. J Am Coll Cardiol 1998;31:
1460–5.
3. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive
protein at discharge in patients with unstable angina predict recurrent
instability. Circulation 1999;99:855–60.
4. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of
myocardial damage and inflammation in relation to long-term mor-
tality in unstable coronary artery disease. FRISC Study Group.
Fragmin during Instability in Coronary Artery Disease. N Engl J Med
2000;343:1139–47.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
194 Liuzzo et al. JACC Vol. 49, No. 2, 2007
CRP, NF-B, and Unstable Angina January 16, 2007:185–945. Muller C, Buettner HJ, Hodgson JM, et al. Inflammation and
long-term mortality after nonST elevation acute coronary syndromes
treated with a very early invasive strategy in 1042 consecutive patients.
Circulation 2002;105:1412–5.
6. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach
to risk stratification in nonST elevation acute coronary syndromes:
simultaneous assessment of troponin I, C-reactive protein, and B-type
natriuretic peptide. Circulation 2002;105:1760–3.
7. Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory
response to coronary angioplasty in patients with severe unstable
angina. Circulation 1998;98:2370–6.
8. Liuzzo G, Biasucci LM, Gallimore JR, et al. Enhanced inflammatory
response in patients with pre-infarction unstable angina. J Am Coll
Cardiol 1999;34:1696–703.
9. Liuzzo G, Angiolillo DJ, Buffon A, et al. Enhanced response of blood
monocytes to in vitro lipopolysaccharide-challenge in patients with
recurrent unstable angina. Circulation 2001;103:2236–41.
0. Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription
factor in chronic inflammatory diseases. N Engl J Med 1997;336:
1066–71.
1. Collins T, Cybulsky MI NF-kappa B: pivotal mediator or innocent
bystander in atherogenesis? J Clin Invest 2001;107:255–64.
2. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the
heart. J Am Coll Cardiol 2001;38:307–14.
3. Monaco C, Andreakos E, Kiriakidis S, et al. Canonical pathway of
nuclear factor kappa B activation selectively regulates proinflammatory
and prothrombotic responses in human atherosclerosis. Proc Natl
Acad Sci U S A 2004;101:5634–9.
4. Ritchie ME. Nuclear factor-kappa B is selectively and markedly
activated in humans with unstable angina pectoris. Circulation 1998;
98:1707–13.
5. Cominacini L, Anselmi M, Garbin U, et al. Enhanced plasma levels of
oxidized low-density lipoprotein increase circulating nuclear factor-
kappa B activation in patients with unstable angina. J Am Coll Cardiol
2005;46:799–806.
6. Wilson SH, Best PJ, Edwards WD, et al. Nuclear factor-kappaB
immunoreactivity is present in human coronary plaque and enhanced
in patients with unstable angina pectoris. Atherosclerosis 2002;160:
147–53.
7. Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C reactive
protein distribution: its relation to development of atherosclerosis.
Atherosclerosis 1999;145:375–9.
8. Torzewski M, Rist C, Mortensen RF, et al. C-Reactive protein in the
arterial intima: role of C-reactive protein receptor-dependent mono-
cyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol
2000;20:2094–98.
9. Calabró P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated
C-reactive protein production by human coronary artery smooth
muscle cells. Circulation 2003;108:1930–2.
0. Lagrand WK, Visser CA, Hermens WT, et al. C-Reactive protein as
a cardiovascular risk factor. More than an epiphenomenon? Circula-
tion 1999;100:96–102.
1. Pepys MB, Hirschfield GM. C-reactive protein: a critical update.
J Clin Invest 2003;111:1805–12.
2. Yeh ET, Anderson HV, Pasceri V, Willerson JT. C-Reactive protein:
linking inflammation to cardiovascular complications. Circulation
2001;104:974–5.
3. van Deventer SJ, Buller HR, ten Cate JW, Sturk A, Pauw W.
Endotoxemia: an early predictor of septicemia in febrile patients.
Lancet 1988;1:605–11.
4. Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IB–
NF-B signaling module: temporal control and selective gene activa-
tion. Science 2002;298:1241–5.
5. Liuzzo G, Vallejo AN, Kopecky SL, et al. Molecular fingerprint of
interferon-gamma signaling in unstable angina. Circulation 2001;103:
1509–14.
6. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of IL-6 in
unstable angina. Circulation 1996;94:874–7.7. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell
activation by C-reactive protein. Cardiovasc Res 2003;58:186–95.
8. Nakakuki T, Ito M, Iwasaki H, et al. Rho/Rho kinase pathway
contributes to C-reactive protein-induced plasminogen activator
inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc
Biol 2005;25:2088–93.
9. Verma S, Badiwala MV, Weisel RD, et al. C-Reactive protein
activates the nuclear factor-kappaB signal transduction pathway in
saphenous vein endothelial cells: implications for atherosclerosis and
restenosis. J Thorac Cardiovasc Surg 2003;126:1886–91.
0. Devaraj S, Kumaresan PR, Jialal I. Effects of C-reactive protein on
chemokine expression in human aortic endothelial cells. J Mol Cell
Cardiol 2004;36:405–10.
1. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and
atherogenesis. Binding of CRP to degraded, nonoxidized LDL en-
hances complement activation. Arterioscler Thromb Vasc Biol 1999;
19:2348–54.
2. Ballou SP, Lozanski G. Induction of inflammatory cytokine release
from cultured human monocytes by C-reactive protein. Cytokine
1992;4:361–8.
3. Pue CA, Mortensen RF, Marsh CB, Pope HA, Wewers MD. Acute
phase levels of C-reactive protein enhance IL-1 and IL-1ra produc-
tion by human blood monocytes but inhibit IL-1 and IL-1ra
production by alveolar macrophages. J Immunol 1996;156:1594–600.
4. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM.
C-Reactive protein induces human peripheral blood monocytes to
synthesize tissue factor. Blood 1993;82:513–20.
5. Nakagomi A, Freedman SB, Geczy CL. Interferon- and lipopoly-
saccharide potentiate monocyte tissue factor induction by C-reactive
protein: relationship with age, sex, and hormone replacement treat-
ment. Circulation 2000;101:1785–91.
6. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of
C-reactive protein on human endothelial cells. Circulation 2000;102:
2165–8.
7. Pasceri V, Chang J, Willerson JT, Yeh ET, Chang J. Modulation of
C-reactive protein-mediated monocyte chemoattractant protein-1
induction in human endothelial cells by antiatherosclerosis drugs.
Circulation 2001;103:2531–4.
8. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and
interleukin-6 inhibition attenuate the proatherogenic effects of
C-reactive protein. Circulation 2002;105:1890–6.
9. Venugopal SK, Devaraj S, Jialal I. C-Reactive protein decreases
prostacyclin release from human aortic endothelial cells. Circulation
2003;108:1676–8.
0. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy:
C-reactive protein attenuates nitric oxide production and inhibits
angiogenesis. Circulation 2002;106:913–9.
1. Wang CH, Li SH, Weisel RD, et al. C-Reactive protein upregulates
angiotensin type 1 receptors in vascular smooth muscle. Circulation
2003;107:1783–90.
2. Verma S, Kuliszewski MA, Li SH, et al. C-Reactive protein attenuates
endothelial progenitor cells survival, differentiation, and function.
Further evidence of a mechanistic link between C-reactive protein and
cardiovascular disease. Circulation 2004;109:2058–67.
3. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-
kappaB and stimulation of inhibitor kappaB by troglitazone: evidence
for an antiinflammatory effect and a potential antiatherosclerotic effect
in the obese. J Clin Endocrinol Metab 2001;86:1306–12.
4. Monaco C, Paleolog E. Nuclear factor kappaB: a potential therapeutic
target in atherosclerosis and thrombosis. Cardiovasc Res 2004;61:671–82.
5. Ridker PM, Cannon CP, Morrow D, et al. C-Reactive protein
levels and outcomes after statin therapy. N Engl J Med 2005;352:
20–8.
6. Nissen SE, Tuzcu EM, Schoenhagen P. Statin therapy, LDL choles-
terol, C-reactive protein, and coronary artery disease. N Engl J Med
2005;352:29–38.
